Venclexta's approval in CLL is important, but another drug making its way to market could reduce its use someday.
Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.
With the Allergan merger now dead, Pfizer will probably look to these catalysts to improve its valuation.
New drug approvals on the horizon set the stage for a market share brawl.
With Allergan now in the rearview mirror, Pfizer may seek to the move the needle by acquiring one of these three drug developers.
Despite AstraZeneca's strategy to return to growth, income investors may still want to focus their attention on AbbVie.
Among the largest drugmakers, there are some large dividend yields, but one stands out as most likely to pay off handsomely for investors down the road.
A new competitor to its top-selling drug could be on deck.
These three drugs could be losing patent protection in the next 12 months.
A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.